
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc is demonstrating strong potential for positive advancements in its therapeutic development for Oculopharyngeal Muscular Dystrophy (OPMD), evidenced by consistent improvements observed in three patients during follow-ups, indicating the efficacy of its treatment approach. The company is on track to double its patient cohort from three to six in the fourth quarter, which could serve as a critical catalyst for further enhancing its clinical outcomes and data robustness. Additionally, with plans to escalate to a higher dose in the fourth quarter of 2025, Benitec Biopharma is positioning itself strategically to advance its innovative genetic medicines, reflecting a favorable outlook for sustained development and potential market impact.
Bears say
Benitec Biopharma Inc is facing significant challenges that contribute to a negative outlook on its stock. The company is at risk of delays or failures in obtaining regulatory approval for its therapies, particularly BB-301, which could adversely affect its share price and investor confidence. Furthermore, the anticipated need for additional equity financing raises concerns about dilution for existing shareholders, compounding the financial risks associated with the inherent uncertainties of clinical trials and competitive pressures in the biotechnology sector.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares